

Tablica 11.1. Prvih 30 lijekova po financijskoj potrošnji izraženo u kunama, na teret HZZO-a u 2019. godini

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	169.380.446
2	V06DX03	namirnice za enteralnu primjenu	101.171.816
3	M09AX07	nusinersen	100.358.904
4	L01XC07	bevacizumab	99.591.530
5	L01XC03	trastuzumab	91.408.514
6	B01AF01	rivaroksaban	79.930.817
7	L01XC13	pertuzumab	79.685.983
8	N05AX13	paliperidon	78.578.815
9	A02BC02	pantoprazol	73.123.775
10	C10AA05	atorvastatin	67.083.859
11	L01XC02	rituksimab	63.154.537
12	L01XE27	ibrutinib	61.751.046
13	J06BA02	imunoglobulini, humani, za i.v. primjenu	61.488.207
14	B01AE07	dabigatran eteksilat	58.385.339
15	M01AE01	ibuprofen	55.062.974
16	J01CR02	amoksisilin i inhibitor enzima	50.690.812
17	L02BB04	enzalutamid	50.663.209
18	J05AP57	glekaprevir, pibrentasvir	49.744.396
19	L04AB04	adalimumab	48.072.754
20	L01XC24	daratumumab	47.553.777
21	C07AB07	bisoprolol	45.263.200
22	L01XC17	nivolumab	45.261.534
23	A10AD05	inzulin aspart	45.127.435
24	N05AH03	olanzapin	44.666.729
25	C09BX01	perindopril, amlodipin i indapamid	42.772.030
26	L04AX04	lenalidomid	42.704.498
27	B05BB01	elektroliti	42.264.944
28	L04AB02	infliksimumab	41.434.110
29	L02BX03	abirateron	40.977.113
30	L01XX32	bortezomib	40.886.404